Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05312671 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

StatusRecruiting
PhasePhase 2
Started2022-06-27
View on ClinicalTrials.gov ↗

Amendment history

2026-06-23
Study Status v6
Re-verified, no change to tracked fields
2025-06-25
Study Status v5
Primary completion date2025-06→2027-10
Completion date2027-06→2029-10
2024-07-01
Study Status, Contacts/Locations v4
Study sitescontacts updated at 1 of 2 sites
2024-06-04
Study Status v3
Primary completion date2024-06→2025-06
Completion date2026-06→2027-06
2023-06-22
Study Status v2
Re-verified, no change to tracked fields
2022-06-27
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2024-11→2024-06
Completion date2026-11→2026-06
Start dateestimated 2022-05→confirmed 2022-06-27
Study sitesdetails revised at 2 of 2 sites
2022-03-28
Original filing
This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and etoposide for patients with locally advanced urothelial cancer. The primary goal of this trial is to assess the pathologic complete response rate at cystectomy in patients after being treated with a combination therapy of atezolizumab, platinum, and etoposide.
Trial Details
NCT Number NCT05312671
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Genentech, Inc.
Conditions Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder
Enrollment 63 participants
Start Date 2022-06-27
Primary Completion 2027-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-25